Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
| Revenue (TTM) | $830.44M |
| Gross Profit (TTM) | $605.31M |
| EBITDA | $110.43M |
| Operating Margin | -2.49% |
| Return on Equity | -10.50% |
| Return on Assets | 0.39% |
| Revenue/Share (TTM) | $14.46 |
| Book Value | $17.73 |
| Price-to-Book | 2.72 |
| Price-to-Sales (TTM) | 3.38 |
| EV/Revenue | 2.978 |
| EV/EBITDA | 51.86 |
| Quarterly Earnings Growth (YoY) | 11.10% |
| Quarterly Revenue Growth (YoY) | 32.40% |
| Shares Outstanding | $58.13M |
| Float | $51.67M |
| % Insiders | 4.46% |
| % Institutions | 106.75% |
Volatility is currently expanding
Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this con.
EDRY, OPBK, SUPN, MSBI and NXRT have been added to the Zacks Rank #1 (Strong Buy) List on August 7th, 2026.
BCAL, SUPN and NXRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 7th, 2026.
Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.
Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) related to its sale to Indivior Pharmaceuticals, Inc. Under the terms of the proposed transaction, Supernus shareholders are expected to receive 1.5401 common shares of Indivior for each share of Supernus.
MILWAUKEE, Aug. 3, 2026 /PRNewswire/ -- Ademi LLP is investigating Supernus (Nasdaq: SUPN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Indivior Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation con.
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SUPN and any ticker you trade — then tracks every position and per-strategy win rate.
